Find Academic Supervisors

Anastasia Semykina is a Professor of Economics and Deputy Dean (Research and Innovation) at RMIT University's School of Economics, Finance & Marketing. She holds a PhD from Michigan State University (2006) and previously served as Charles and Joan Haworth Professor of Economics at Florida State University. Her expertise spans theoretical and applied econometrics, with a focus on panel data models, missing data estimation, and their application in labor economics, education economics, transition economies, and economic psychology. She teaches advanced econometrics and microeconomics courses at both undergraduate and graduate levels. Research Interests: Theoretical and Applied Econometrics Labor Economics Economics of Education Transition Economies Economics and Psychology Health Economics Her recent publications address topics such as panel data methodologies, healthcare cost-effectiveness analysis, and educational policy evaluation. She is actively involved in supervising PhD and Master's research students in econometrics and applied economics.

• Theoretical Econometrics
• Applied Econometrics
• Labor Economics
• +4 more

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +3 more

Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)

• Nanomedicine
• Therapeutic Targeting
• Drug Delivery Systems
• +4 more

About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.

• Cancer Targeting
• Drug Design
• Drug Delivery
• +4 more

Dr. Owen Dillon is a Research Fellow in the Discipline of Medical Imaging Sciences at the University of Sydney's Faculty of Medicine and Health. He holds affiliations with the ACRF Image X Institute and the Dodd-Walls Centre for Photonic and Quantum Technologies. His work focuses on advanced imaging techniques for medical applications, particularly computed tomography (CT) and motion compensation in radiation therapy. He completed his PhD in Mathematics at the University of Auckland, specializing in probabilistic compression algorithms for inverse problems. Education: B.Sc. Physics & Applied Mathematics (2013, University of Auckland), First Class Honours in Mathematics (2015), PhD Mathematics (2018). Research interests include inverse problems, Bayesian statistics, CT image reconstruction, and real-time imaging systems. Current projects involve optimizing CT acquisition geometries, motion-compensated 4D imaging, and anatomical motion estimation. His contributions have led to clinical trials reducing radiation dose and scan times. He advises two PhD students and collaborates on grants like the Quantum CT project. Grants: 'Quantum CT for Cancer Diagnosis' (2024), 'Functional Imaging in Lung Cancer' (2024). His work bridges mathematical theory with clinical applications in oncology and interventional radiology.

• Medical Imaging
• Computed Tomography
• Inverse Problems
• +3 more

Dr. Nhiem Tran is a Senior Lecturer in the Department of Applied Chemistry and Environmental Science at RMIT University's School of Science, part of the STEM College. He joined RMIT in 2015 as a Vice Chancellor's Research Fellow after completing his PhD in Physics at Brown University (USA, 2012) and postdoctoral research at Rhode Island Hospital (USA), CSIRO, and the Australian Synchrotron. His research focuses on developing biomaterials for drug delivery, gene therapy, and medical implants, particularly lipid nanoparticles and 3D-printed metallic implants. He leads the Biomaterial Interfaces group, investigating self-assembled lipid nanoparticles for cancer and autoimmune disease treatments. His work has resulted in over 65 high-impact publications and numerous awards, including the RMIT Vice Chancellor's Research Fellowship and the Stein/Bellet Foundation Fellowship. Tran's funding comes from grants such as the ARC Discovery Project, mRNA Victoria, and the CASS Foundation. His research interests span nanomedicine, biomedical engineering, and materials science, with a focus on applications in drug delivery, bacterial infection control, and orthopaedic implants. Education: PhD in Physics (Brown University, 2012) Key Projects: 3D-printed diamond-titanium implants, lipid nanoparticle drug carriers, and antimicrobial coatings. He actively supervises postgraduate research in areas like nanomaterials for drug delivery and biomedical applications.

• Biomedical Engineering
• Nanotechnology
• Nanomedicine
• +12 more

Janani Thillainadesan is an NHMRC Senior Research Fellow at the Sydney Medical School/Concord Clinical School and the Centre for Education and Research on Ageing, affiliated with the Faculty of Medicine and Health at the University of Sydney. She is also a member of the Charles Perkins Centre. Her research focuses on optimizing healthcare delivery for older adults, particularly in geriatric surgery, perioperative care, and dementia interventions. Key research areas include frailty assessment, deprescribing strategies, collaborative care models, and leveraging technology (e.g., mobile health) in geriatric medicine. She has contributed to multidisciplinary studies involving clinical datasets, quality indicators, and mixed-methods analyses of patient experiences and care expectations. Awards: 2023 RACP Vincent Fairfax Research Fellowship 2021 ANZSGM Career Investigator Prize 2021 UK Age Anaesthesia Association Best Oral Presentation Prize 2019 Evidence Based Perioperative Medicine Asia Congress Runner Up Prize Her work bridges clinical practice, education, and policy through grants like the 2024 electronic frailty index project. Media engagement includes a 2019 Studio 10 segment highlighting her contributions to aging-related healthcare innovations.

• Health services for older people
• Collaborative models of care
• Frailty
• +4 more

Dr. Suresh Bhargava is a Distinguished Professor and Director of AcSIR at RMIT University's Research & Innovation department. He has led interdisciplinary research in materials science, catalysis, and environmental engineering for over three decades, with a focus on strengthening Indo-Australian scientific collaboration. His work bridges academia and industry, addressing challenges in pollution control, nanotechnology, and cancer treatment. Research & Leadership: Established RMIT's Centre for Advanced Materials and Industrial Chemistry (CAMIC), pioneering translational research with industry applications. Supervised 70+ PhD students (100% employment rate), many now leading roles at global institutions. Holds distinguished professorships across six countries and advises governments and Fortune 500 firms on environmental and industrial issues. Awards & Recognition: Recipient of Australia's Member of the Order of Australia (2022), India's P.C. Ray Chair (2014), and the Khwarizmi International Award (2016). His work on mercury pollution control and gold-based anticancer drugs has garnered global acclaim, with over 800 publications (26,000+ citations, h-index 86). Key Contributions: Architect of the Australia-India Strategic Research Fund and the RMIT-AcSIR Joint Research Program. Innovated eco-friendly graphene production from eucalyptus bark and patented anti-cancer gold compounds. Advises on sustainable mineral processing, hydrogen energy, and CO₂ valorization. Industry Engagement: Consulted for Rio Tinto, BHP Billiton, and CSIRO on resource efficiency, pollution mitigation, and nanotechnology applications. His research has created jobs and driven innovation in Australia and Asia-Pacific.

• Catalysis
• Nanotechnology
• Environmental Chemistry
• +3 more

Zeyad Ibrahim is a Doctor of Philosophy student at the University of Western Australia, engaged in Casual Teaching and acting as a Multi-Discipline Contractor/Visitor. Affiliated with the School of Allied Health, UWA Medical School, and the UWA Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), he focuses on pharmacogenomics in pediatric cancer treatment. Education: Doctor of Philosophy, School of Allied Health, University of Western Australia. Research interests include methotrexate pharmacogenomics, CRISPR/Cas9 genomic models for drug efficacy assessment, and systematic reviews addressing gaps in pediatric cancer therapies. His work aligns with UN Sustainable Development Goals related to health and well-being. Publications include two peer-reviewed abstracts in the Asia-Pacific Journal of Clinical Oncology (2019), exploring methotrexate pharmacogenomics in pediatric cancers and a CRISPR-based genomic model. He received the Churchill Fellowship 2022 for pharmacogenomics research. Grants: Co-investigator on two major projects funded by the Western Australian Department of Health, focusing on personalized cancer treatment using pharmacogenomics to improve outcomes and reduce costs for seriously ill children (MiSSK initiative). Labs/Teams: Involved with the Centre for Optimisation of Medicines and collaborates with the Harry Perkins Institute of Medical Research.

• Pharmacogenomics
• Cancer Treatment
• Pediatric Oncology
• +3 more

Dr. Mark Gardner is a Research Fellow in Clinical Imaging at the ACRF Image X Institute, part of the University of Sydney's Sydney School of Health Sciences and Faculty of Medicine and Health. His work focuses on advancing radiation therapy and medical imaging technologies, with particular emphasis on improving treatment accuracy and patient comfort. Gardner holds a PhD from Flinders University, completed in collaboration with the Medical Device Research Institute, and has held research roles at the Cystic Fibrosis Airway Research Group (CFARG). His current projects include the Nano-X radiation therapy device and the Remove the Mask initiative , which aims to eliminate immobilization masks in head and neck cancer treatments. Gardner is affiliated with organizations like the IEEE Engineering in Medicine and Biology Society and the American Association of Physicists in Medicine. Research interests span radiation oncology, translational research in medical imaging, and device innovation. His work integrates advanced imaging techniques (e.g., synchrotron X-rays, cone-beam CT) with machine learning and wearable sensors to address challenges in respiratory therapy and tumor targeting. Notable contributions include developing real-time motion tracking for radiation therapy and improving mucociliary transport measurements. Awards: FameLab 2020 State Finalist, 2018 Medtech e-Challenge Winner, 2017 3MT Runner-Up Grants/Projects: Nano-X radiation therapy development, Remove-the-Mask surface-guided system Collaborations: Industry partnerships, multi-institutional research networks Gardner advises Chen Cheng on real-time head/neck motion monitoring during radiation therapy. His lab contributes to open-source tools and preclinical imaging advancements, bridging engineering and clinical oncology.

• Radiotherapy
• Medical Imaging
• Clinical Imaging
• +3 more

Edward Ashworth is a Postdoctoral Research Associate at the Sydney School of Health Sciences, University of Sydney. He is affiliated with the Thermal Ergonomics Laboratory and the Heat and Health Research Incubator. His research focuses on human adaptations to extreme environments, including heat, altitude, hyperbaric conditions, and space-related stressors. Key projects include improving sleep quality in hot environments and enhancing physical work capacity for outdoor workers. Edward's research interests span environmental physiology, with a focus on thermal tolerance, radiation injury mitigation, and the physiological effects of extreme conditions. He has contributed to studies involving nitrogen kinetics tracking using PET imaging, hyperbaric oxygen therapy, and robotic surgery applications. Awards: Young Investigator Award (2023), Art of Science Contest 1st Prize (2024), Australia Space Biology Summit 1st Place (2022), and Sporting Blue (Auckland University of Technology). Associations: The Physiological Society and American Physiological Society. His work integrates clinical trials, statistical research design, and translational approaches to address challenges in environmental health, cardiovascular disease, and healthy ageing. Current projects aim to optimize thermal tolerance strategies for military and occupational settings.

• Extreme Environmental Physiology
• Human Adaptation to Stressful Environments
• Environmental Health
• +3 more

Associate Professor Ken Chung is affiliated with the University of Sydney's School of Project Management, serving as Associate Head of Education. He holds a PhD (University of Sydney) and dual undergraduate degrees (B.Sc (Hons I), B.Com). His research focuses on social network theory applied to stakeholder engagement in projects, healthcare coordination, and complex systems. Notable awards include the 2021 Faculty of Engineering Dean's Award for Excellence in Teaching and a PMI grant for infrastructure stakeholder engagement research. He has collaborated with organizations like NSW Department of Planning, Google, and Western Sydney Airport. Teaching includes courses like ENGG1850 and PMGT5871. Current projects explore stakeholder analysis, community engagement in infrastructure, and healthcare networks. His expertise spans 20+ years, with international partnerships at Webster Vienna and University of Southern Denmark. Professional activities include editorial roles, ARC grant reviewing, and industry advisory roles. Education highlights: PhD in Information Technologies (2009, Sydney), prior lectureship at University of Wollongong. Industry experience includes Telstra Messaging Group and DoubleClick Australia. Research integrates social physics principles, examining network structures' impact on project success, healthcare outcomes, and organizational behavior. Grants include ARC DP-funded health research and PMI-funded infrastructure studies. Key themes include network-based models for stakeholder engagement, project management innovation, and social capital utilization.

• Stakeholder Engagement
• Social Network Theory
• Project Management
• +4 more

Dr. Joseph Choi is a Clinical Lecturer and General Surgery Fellow at the University of Sydney's Westmead Clinical School, within the Discipline of Surgery under the Faculty of Medicine and Health. He holds academic qualifications including BSc(Adv), MBBS, MPhil, and FRACS. His clinical and research interests focus on surgical outcomes, colorectal surgery, endometriosis management, and minimally invasive techniques. Dr. Choi's research emphasizes surgical complications, anastomotic leak prediction, and emerging surgical technologies. He has contributed to over 30 peer-reviewed publications since 2011, with recent work addressing robotic surgery feasibility, Strongyloides stercoralis infections, and HER2 therapy outcomes in breast cancer. His academic profile includes collaborations with multidisciplinary teams across oncology, gastroenterology, and gynecology. No formal awards or grants are explicitly listed, though his prolific publication record reflects sustained scholarly activity.

• General Surgery
• Colorectal Surgery
• Endometriosis Surgery
• +3 more

Professor Joy Ho is a Clinical Professor of Medicine at the University of Sydney’s Central Clinical School and a Senior Staff Specialist in Haematology at Royal Prince Alfred Hospital (RPAH). She serves as Director of Research and Head of the Multiple Myeloma Research Unit and Thalassemia/Haemoglobinopathy Unit at the Institute of Haematology, RPAH. Her research focuses on multiple myeloma, lymphoma, thalassemia, and iron metabolism, with a strong emphasis on clinical trials and translational medicine. She has led numerous multi-centre trials, including pioneering studies on CAR-T cell therapy for lymphoma and novel therapies for myeloma. Prof Ho’s education includes MB.BS. (Hons) from Sydney, D.Phil (Oxford), and fellowships from the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA). She has held leadership roles in major hematology organizations, including the International Myeloma Working Group (IMWG) and the American Society of Hematology (ASH). Her international collaborations span Singapore, Thailand, and the United States. Her research interests include: Multiple Myeloma: Developing therapies targeting tumor microenvironment and immune modulation. Lymphoma: Pioneering CAR-T cell therapy in Australia. Thalassemia: Gene therapy and iron chelation advancements, including the landmark Northstar trial. Iron Metabolism: Investigating hepcidin and its role in transfusion-dependent anemias. Her recent publications highlight breakthroughs in CAR-T efficacy, myeloma biomarkers, and thalassemia management. Awards include the 2019 Sydney Local Health District Clinical Trial Award and election to the International Myeloma Society Board. She has secured over $2 million in grants for cutting-edge equipment and research. Prof Ho’s academic contributions extend to teaching and supervision, training fellows for RACP/RCPA certifications. Her leadership in national registries (e.g., Australian Haemoglobinopathy Registry) and guidelines (e.g., iron chelation protocols) underscores her commitment to advancing hematology care globally.

• Multiple Myeloma
• Lymphoma
• Thalassemia
• +5 more

Dr. Jannah Baker is a Research Fellow at the Sydney School of Public Health, University of Sydney. She holds a PhD in Statistics specializing in Bayesian spatiotemporal modelling of chronic diseases, alongside dual postgraduate diplomas in Public Health and Statistics. Her clinical background includes five years as a practicing physician. Her research focuses on cancer prevention (breast, endometrial, melanoma), spatiotemporal disease modeling, health economics, and clinical trial design. She has led projects on sepsis detection systems, diabetes management, and surgical outcomes analysis. Notable contributions include a seminal systematic review on fertility-sparing endometrial cancer treatments referenced in international guidelines. Jannah has attracted $6M+ in collaborative funding and oversees grants such as the 2023 NHMRC-funded ROADMAP trial and a Department of Health-funded study on pediatric sepsis management. Her work spans 50+ peer-reviewed articles across journals like Journal of Medical Internet Research and PLOS One . Professional activities include clinical trials statistics, health economics analysis, and implementation science lectures. She has mentored multiple research teams and maintains an ORCID profile (0000-0002-2208-6584).

• Breast Cancer Prevention
• Spatiotemporal Disease Modelling
• Health Economics
• +3 more